A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964)
10/2002
10/29/2002	US6471960 Methods for the prevention or treatment of alzheimer's disease
10/29/2002	US6471957 Canine IL-4 immunoregulatory proteins and uses thereof
10/29/2002	US6471956 Ob polypeptides, modified forms and compositions thereto
10/24/2002	WO2002084757A1 Heterostructure component
10/24/2002	WO2002084294A2 Gastrointestinal glutathione peroxidase in hepatitis c virus infections
10/24/2002	WO2002083950A1 Methods and compositions for treating cardiovascular disease using 10218
10/24/2002	WO2002083945A2 Diagnosis and treatment of cancer: i
10/24/2002	WO2002083928A2 Nucleid acid and corresponding protein entitled 158p3d2 useful in treatment and detection of cancer
10/24/2002	WO2002083921A2 Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers
10/24/2002	WO2002083920A2 Nucleic acid sequences useful in the detection and treatment of various cancers
10/24/2002	WO2002083919A2 Nucleic acid and corresponding protein entitled 184p1e2 useful in treatment and detection of cancer
10/24/2002	WO2002083917A2 Nucleic acid and corresponding protein entitled 161p5c5 useful in treatment and detection of cancer
10/24/2002	WO2002083916A2 Nucleic acid and corresponding protein entitled 162p1e6 useful in treatment and detection of cancer
10/24/2002	WO2002083909A2 Recombinant nucleotide sequence coding for a gene
10/24/2002	WO2002083908A1 Method for reversible inhibition of gene expression by modified ribonucleoproteins
10/24/2002	WO2002083902A2 Adenovirus serotype 30 (ad30) fiber protein and uses thereof
10/24/2002	WO2002083898A1 Full-length human cdnas encoding potentially secreted proteins
10/24/2002	WO2002083892A2 Mutants of desoxycytidine kinase having extended enzymatic activity
10/24/2002	WO2002083891A2 Nucleic acids for inhibiting hairless protein expression and methods of use thereof
10/24/2002	WO2002083870A2 Pufa polyketide synthase systems and uses thereof
10/24/2002	WO2002083866A2 Repeat sequences of the ca125 gene and their use for diagnostic and therapeutic interventions
10/24/2002	WO2002083860A2 Nucleic acid and corresponding protein entitled 151p3d4 useful in treatment and detection of cancer
10/24/2002	WO2002083859A2 Surface proteins of streptococcus pyogenes
10/24/2002	WO2002083855A2 Novel streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof
10/24/2002	WO2002083850A2 Vascular endothelial growth factor 2
10/24/2002	WO2002083847A2 Cdna encoding the human alpha2 delta4 calcium channel subunit
10/24/2002	WO2002083840A2 Compositions and methods for transepithelial transport of membrane-bounded vesicles and virions
10/24/2002	WO2002083736A2 G-protein coupled receptor molecules and uses thereof
10/24/2002	WO2002083727A2 Nucleic acid sequences of hyperplasies and tumors of the thyroid
10/24/2002	WO2002083725A1 Novel stress protein with chaperone activity
10/24/2002	WO2002083714A2 Method and system for optimizing multi-epitope nucleic acid constructs and peptides encoded thereby
10/24/2002	WO2002083707A1 Tub antisense constructs
10/24/2002	WO2002083705A1 Socs-1 gene methylation in cancer
10/24/2002	WO2002083704A1 Vascular endothelial growth factor 2
10/24/2002	WO2002083186A1 Nuclear receptor-mediated introduction of a pna into cell nuclei
10/24/2002	WO2002083185A1 Method of gene transfer via vascular system or ureter
10/24/2002	WO2002083184A2 Gene therapy with chimeric oligonucleotides delivered by a method comprising a step of iontophoresis
10/24/2002	WO2002083183A2 Stimulation of the immune system
10/24/2002	WO2002083182A2 The effect of receptor protein tyrosine phosphatase sigma (rptp-$g(s)) on neural axon regeneration and synapse modification
10/24/2002	WO2002083181A1 Novel compositions and uses therefor
10/24/2002	WO2002083096A1 Modification of the sustained release profile
10/24/2002	WO2002083080A2 Method of treating arthritis using lentiviral vectors in gene therapy
10/24/2002	WO2002083075A2 Akt and regulation of ra synovial fibroblast apoptosis
10/24/2002	WO2002083060A2 Use of amino acid transporter atb0,+ as a delivery system for drugs and prodrugs
10/24/2002	WO2002082908A1 Method of treating arthritis using lentiviral vectors in gene therapy
10/24/2002	WO2002082904A2 Method of treating or retarding the development of blindness
10/24/2002	WO2002066078A3 Modulated release particles for aerosol delivery
10/24/2002	WO2002066077A3 Modulated release particles for aerosol delivery
10/24/2002	WO2002064746A3 Combined transductional and transcriptional targeting system for improved gene delivery
10/24/2002	WO2002048380A3 Glycosilated cationic lipids for liposomes used in drug delivery
10/24/2002	WO2002046367A3 Antisense modulation of cellular apoptosis susceptibility gene expression
10/24/2002	WO2002040715A8 Molecules for disease detection and treatment
10/24/2002	WO2002040038A3 M. tuberculosis chaperonin 10 and uses thereof
10/24/2002	WO2002022830A3 Transglutaminase gene products
10/24/2002	WO2002000210A3 Use of agents capable of reducing uric acid levels for the treatment of cardiovascular disease
10/24/2002	WO2001077375A8 Diagnosis of diseases associated with gene regulation
10/24/2002	WO2001068911A8 Diagnosis of diseases associated with the cell cycle
10/24/2002	WO2001068135A9 Compositions and methods for affecting osteogenesis
10/24/2002	WO2001061005A3 Molecules of the pyrin domain protein family and uses thereof
10/24/2002	WO2001059103A9 Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression
10/24/2002	WO2001055337A3 Methods and materials relating to carcinoembryonic antigen-like (cea-like) polypeptides and polynucleotides
10/24/2002	WO1999064449A3 Cell-permeable peptide
10/24/2002	US20020157125 Growth differentiation factor-8
10/24/2002	US20020157121 Propagation of human hepatocytes in non-human animals
10/24/2002	US20020156261 Wherein secondary structure disintegrates upon attachment of the oligonucleotide to a target nucleic acid; anticarcenogenic agents, treatment of Ewing's sarcoma
10/24/2002	US20020156258 Transcription factor of MHC class II genes, substances capable of inhibiting this new transcription factor and medical uses of these substances
10/24/2002	US20020156252 Novel Stra6 polypeptides
10/24/2002	US20020156243 Adipocyte-specific protein homologs
10/24/2002	US20020156123 Novel pharmaceutical compositions for modulating angiogenesis
10/24/2002	US20020156045 Magnesium chloride improves efficiency of transfection of polynucleotide; drug delivery; vaccination
10/24/2002	US20020156044 Use of EXT genes for the treatment of cancer and other diseases
10/24/2002	US20020156042 Human suppressor tRNA oligonucleotides and methods of use for same
10/24/2002	US20020156041 Non-squamous epithelium-specific transcription
10/24/2002	US20020156037 DNA vaccine formulations
10/24/2002	US20020156035 NET-4 is a member of the tetraspan transmembrane receptor family; antisense molecules, ribozymes, antibodies and antibody fragments for reductin NET-4 gene expression or activity; antitumor agents
10/24/2002	US20020156034 Chemokine receptor antagonists, including peptide antagonists of CXC chemokine receptor 4 (CXCR4) for use in the treatment of hematopoietic (stem/progenitor) cells; mobilize the these cells from marrow to peripheral blood; gene therapy
10/24/2002	US20020156032 Inhibition of DNA methyltransferase
10/24/2002	US20020156031 A DNA segment comprising a protein coding region encoding an Osterix polypeptide; gene therapy; osteoporosis; recombinant Osterix polypeptide
10/24/2002	US20020156007 Apolipoprotein analogues
10/24/2002	US20020156006 Secreted and transmembrane polypeptides and nucleic acids encoding the same
10/24/2002	US20020156001 Novel fibroblast growth factor ( FGF23) and methods for use
10/24/2002	US20020155988 Uses of transport proteins
10/24/2002	US20020155987 Isolated endostatin, especially approximately 20 kDa and corresponds to a C-terminal fragment of collagen type XVIII
10/24/2002	US20020155609 Monocyte-specific particulate delivery vehicle
10/24/2002	US20020155608 Methods for delivering DNA to muscle cells using recombinant adeno-associated virus virions
10/24/2002	US20020155607 Multifunctional molecular complexes for gene transfer to cells
10/24/2002	US20020155602 Vectors, cells and methods for the production of deleterious viral eukaryotic gene transfer vectors
10/24/2002	US20020155601 Method for producing a population of homozygous stem cells having a pre-selected immunotype and/or genotype, cells suitable for transplant derived therefrom, and materials and methods using same
10/24/2002	US20020155597 In vivo production and delivery of erthropoietin or insulinotropin for gene therapy
10/24/2002	US20020155582 Genetically engineered ciral particles for use in the prevention of viral diseases
10/24/2002	US20020155577 Compound for use in the treatment of parkinson's disease
10/24/2002	US20020155569 Regulation of gene expression through manipulation of mRNA splicing and its uses
10/24/2002	US20020155544 Treatment of diabetes with synthetic beta cells
10/24/2002	US20020155539 Calcium channel polynucleotides, polypeptides, and antibodies
10/24/2002	US20020155534 SBHWSB2: a new member of the WD40 SOCS box family
10/24/2002	US20020155533 PACAP receptor protein, method for preparing said protein, and use thereof
10/24/2002	US20020155529 Viral vectors having reduced virulence
10/24/2002	US20020155528 Regulation of human CysLT2-like GPCR protein
10/24/2002	US20020155447 Nucleotide sequences coding polypeptide for use in the treatment of cancer
10/24/2002	US20020155434 Fusion protein for use in the treatment of viral diseases

1 ... 563 564 565 566 567 568 569 570 571 572 573 574 575 576 577 578 579 580 581 582 583 ... 870